Plasma myeloperoxidase level and peripheral arterial disease
European Journal of Clinical Investigation, 05/02/2012
Haslacher H et al. – The authors suggest consideration of plasma Myeloperoxidase (MPO) for risk stratification of major adverse cardiovascular events in patients with peripheral arterial disease. In contrast, MPO–463G>A is not an independent risk factor for major adverse cardiovascular events in patients suffering from peripheral arterial disease.